X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, AbbVie will advance Landos’ lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action, which is anti-inflammatory and facilitates epithelial repair.
Lead Product(s): NX-13
Therapeutic Area: Gastroenterology Product Name: NX-13
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $212.5 million Upfront Cash: $137.5 million
Deal Type: Acquisition March 25, 2024
Details:
The collaboration aims to investigate the effects of NX-13, first-in-class, oral, gut-selective, NLRX1 agonist, on epithelial cells with the Inflammatory Bowel Disease.
Lead Product(s): NX-13
Therapeutic Area: Gastroenterology Product Name: NX-13
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: KU Leuven
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 14, 2023
Details:
BT-11 (omilancor) is a novel, oral, gut-restricted therapeutic targeting the lanthionine synthetase C-like 2 (LANCL2) pathway which decreases the production of key inflammatory mediators causing ulcerative colitis.
Lead Product(s): Omilancor
Therapeutic Area: Gastroenterology Product Name: BT-11
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NImmune Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Details:
NX-13 is a first-in-class novel, gut-selective oral therapeutic candidate that targets NLRX1 that has been associated with the modulation of inflammatory cytokines for UC and CD.
Lead Product(s): NX-13
Therapeutic Area: Gastroenterology Product Name: NX-13
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Details:
Landos Biopharma anticipates using the net proceeds from the investment to advance the development of NX-13 for Ulcerative Colitis and Crohn’s Disease and for other general corporate purposes.
Lead Product(s): NX-13
Therapeutic Area: Gastroenterology Product Name: NX-13
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $16.7 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 05, 2023
Details:
NX-13 is a novel, gut-restricted, orally active, small molecule therapeutic candidate for the treatment of UC. NX-13 targets NLRX1, a mitochondria-associated receptor with the ability to modulate immune responses.
Lead Product(s): NX-13
Therapeutic Area: Gastroenterology Product Name: NX-13
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
Landos Biopharma collaborate with Icahn School of Medicine to conduct a Phase 2 trial of omilancor, a novel, oral, gut-restricted, small-molecule investigational drug that targets the Lanthionine Synthetase C-Like 2 (LANCL2) pathway impacting the gastrointestinal tract.
Lead Product(s): Omilancor
Therapeutic Area: Gastroenterology Product Name: BT-11
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Icahn School of Medicine
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 20, 2021
Details:
Oral treatment with LABP-104 in preclinical models of Systemic Lupus Erythematosus (SLE) resulted in enhanced Treg function, decreased kidney inflammation and reduced interferon gamma signaling.
Lead Product(s): LABP-104
Therapeutic Area: Immunology Product Name: LABP-104
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2021
Details:
Discovered using Landos proprietary LANCE® Advanced A.I. platform, omilancor is a novel, oral, gut-restricted small molecule investigational drug that targets the Lanthionine Synthetase C-Like 2 (LANCL2) pathway impacting the gastrointestinal tract.
Lead Product(s): Omilancor
Therapeutic Area: Gastroenterology Product Name: BT-11
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2021
Details:
LianBio will receive exclusive rights to develop and commercialize BT-11 and NX-13 in Greater China, South Korea, Singapore, Thailand, Vietnam, Myanmar, Cambodia, Indonesia, and the Philippines.
Lead Product(s): Omilancor
Therapeutic Area: Gastroenterology Product Name: BT-11
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: LianBio
Deal Size: $218.0 million Upfront Cash: $18.0 million
Deal Type: Collaboration May 17, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
